CY2021020I1 - Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη - Google Patents
Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψηInfo
- Publication number
- CY2021020I1 CY2021020I1 CY2021020C CY2021020C CY2021020I1 CY 2021020 I1 CY2021020 I1 CY 2021020I1 CY 2021020 C CY2021020 C CY 2021020C CY 2021020 C CY2021020 C CY 2021020C CY 2021020 I1 CY2021020 I1 CY 2021020I1
- Authority
- CY
- Cyprus
- Prior art keywords
- delivery system
- drug delivery
- system consisting
- hormonal contraception
- tetrahydroxylated estrogen
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title 1
- 229940011871 estrogen Drugs 0.000 title 1
- 239000000262 estrogen Substances 0.000 title 1
- 230000003054 hormonal effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01201946 | 2001-05-23 | ||
EP01201947 | 2001-05-23 | ||
EP01201945A EP1293210B1 (en) | 2001-05-23 | 2001-05-23 | Means and method for hormonal contraception |
EP01204377 | 2001-11-15 | ||
EP02075695 | 2002-02-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
CY2021020I1 true CY2021020I1 (el) | 2021-12-31 |
CY2021020I2 CY2021020I2 (el) | 2021-12-31 |
Family
ID=27513107
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100136T CY1108093T1 (el) | 2001-05-23 | 2008-02-04 | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη |
CY2021020C CY2021020I2 (el) | 2001-05-23 | 2021-07-26 | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100136T CY1108093T1 (el) | 2001-05-23 | 2008-02-04 | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη |
Country Status (12)
Country | Link |
---|---|
US (1) | US7732430B2 (el) |
EP (1) | EP1390042B1 (el) |
CA (1) | CA2448278C (el) |
CY (2) | CY1108093T1 (el) |
DE (1) | DE60223795T2 (el) |
DK (1) | DK1390042T3 (el) |
ES (1) | ES2296943T3 (el) |
FR (1) | FR21C1033I2 (el) |
LU (1) | LUC00213I2 (el) |
NL (1) | NL301115I2 (el) |
PT (1) | PT1390042E (el) |
WO (1) | WO2002094279A1 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1556058T1 (sl) | 2002-10-23 | 2008-02-29 | Pantarhei Bioscience Bv | Farmacevtski sestavki, ki obsegajo estetrolne derivate, za uporabo pri zdravljenju raka |
PT1562976E (pt) | 2002-11-08 | 2010-08-12 | Pantarhei Bioscience Bv | Síntese do estetrol via esteróides derivados da estrona |
CA2835979C (en) | 2011-06-01 | 2018-05-01 | Estetra S.A. | Process for the production of estetrol intermediates |
PT2714710T (pt) | 2011-06-01 | 2016-07-12 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
ES2545337T3 (es) * | 2011-07-19 | 2015-09-10 | Pantarhei Bioscience B.V. | Comprimido que contiene dehidroepiandrosterona (DHEA) |
WO2013021025A1 (en) * | 2011-08-11 | 2013-02-14 | Estetra S.A. | Use of estetrol as emergency contraceptive |
WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
JP6254289B2 (ja) | 2013-09-18 | 2017-12-27 | クリスタル ファルマ、エセ、ア、ウCrystal Pharma,S.A.U. | エステトロールの製造プロセス |
CN105979935B (zh) | 2013-12-12 | 2019-07-26 | 多内斯塔生物科学股份有限公司 | 包含雌四醇组分的口崩固体剂量单位 |
EP3310346B1 (en) | 2015-06-18 | 2021-03-24 | Estetra SPRL | Orodispersible tablet containing estetrol |
SI3310333T1 (sl) | 2015-06-18 | 2020-08-31 | Estetra Sprl | Orodisperzibilna enota odmerka, ki vsebuje komponento estetrola |
KR102664563B1 (ko) | 2015-06-18 | 2024-05-09 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 에스테트롤 성분을 함유하는 구강분해성 투여 단위 |
CA2988485A1 (en) | 2015-06-18 | 2016-12-22 | Mithra Pharmaceuticals S.A. | Orodispersible tablet containing estetrol |
CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
MA51733A (fr) * | 2018-02-07 | 2020-12-16 | Estetra Sprl | Composition contraceptive présentant des effets cardiovasculaires réduits |
TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
JOP20200260A1 (ar) | 2018-04-19 | 2019-10-19 | Estetra Sprl | مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث |
HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
WO2023152682A1 (en) | 2022-02-10 | 2023-08-17 | Estetra Srl | Contraceptive methods with scheduled bleeding effects |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3440320A (en) * | 1964-06-18 | 1969-04-22 | Mortimer D Sackler | Chelated suppository and method of using same |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
DE2336434A1 (de) | 1973-07-13 | 1975-04-17 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
DE2426779A1 (de) | 1974-05-31 | 1975-12-18 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
DE2336433A1 (de) | 1973-07-13 | 1975-04-03 | Schering Ag | 1.3-oxygenierte 8 alpha-oestratriene |
US4722941A (en) * | 1978-06-07 | 1988-02-02 | Kali-Chemie Pharma Gmbh | Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof |
US4460372A (en) * | 1981-02-17 | 1984-07-17 | Alza Corporation | Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer |
US4573996A (en) * | 1984-01-03 | 1986-03-04 | Jonergin, Inc. | Device for the administration of an active agent to the skin or mucosa |
US4624665A (en) * | 1984-10-01 | 1986-11-25 | Biotek, Inc. | Method of transdermal drug delivery |
US4937238A (en) * | 1986-03-04 | 1990-06-26 | The Board Of Regents Of The University Of Nebraska | Prevention of mammary carcinoma |
US4762717A (en) * | 1986-03-21 | 1988-08-09 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive |
US5223261A (en) * | 1988-02-26 | 1993-06-29 | Riker Laboratories, Inc. | Transdermal estradiol delivery system |
US5043331A (en) | 1989-06-15 | 1991-08-27 | Orion-Yhtyma Oy | Treatment of postmenopausal disorders |
US5130137A (en) * | 1989-08-09 | 1992-07-14 | The General Hospital Corporation | Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders |
JPH04235171A (ja) | 1990-07-26 | 1992-08-24 | Sumitomo Chem Co Ltd | スルホヒドロキサム酸誘導体、その製造法およびそれを有効成分とする除草剤 |
US5063507A (en) * | 1990-09-14 | 1991-11-05 | Plains Cotton Cooperative Association | Goods database employing electronic title or documentary-type title |
US5340585A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Method and formulations for use in treating benign gynecological disorders |
US5340586A (en) * | 1991-04-12 | 1994-08-23 | University Of Southern California | Methods and formulations for use in treating oophorectomized women |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
US5895783A (en) | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
NL9301562A (nl) * | 1993-09-09 | 1995-04-03 | Saturnus Ag | Preparaat voor substitutietherapie. |
DE4344405C2 (de) * | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
WO1996003929A1 (en) | 1994-08-04 | 1996-02-15 | Biex, Inc. | Method for prediction of premature delivery using estetrol (e4) as an indicator |
DE4429374C1 (de) * | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
WO1998058657A1 (en) | 1997-06-20 | 1998-12-30 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
US6214815B1 (en) * | 1998-12-23 | 2001-04-10 | Ortho-Mcneil Pharmaceuticals, Inc. | Triphasic oral contraceptive |
DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
EP1171091A1 (de) | 1999-04-16 | 2002-01-16 | Jenapharm GmbH & Co. KG | Pharmazeutische oder kosmetische zusammensetzungen zur lokalen, intradermalen applikation von estrogenen |
AU5137900A (en) | 1999-05-28 | 2000-12-18 | University Of Cincinnati, The | Antisense oligonucleotides for fertility and menstrual cycle regulation and for chemopreventive and chemotherapeutic use |
WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
CA2408935A1 (en) | 2000-05-12 | 2001-11-15 | Halina Offner | Method of treating immune pathologies with low dose estrogen |
US6936599B2 (en) * | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
DE60216630T2 (de) * | 2001-11-15 | 2007-09-20 | Pantarhei Bioscience B.V. | Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie |
-
2002
- 2002-05-23 DK DK02738961T patent/DK1390042T3/da active
- 2002-05-23 ES ES02738961T patent/ES2296943T3/es not_active Expired - Lifetime
- 2002-05-23 DE DE60223795T patent/DE60223795T2/de not_active Expired - Lifetime
- 2002-05-23 EP EP02738961A patent/EP1390042B1/en not_active Expired - Lifetime
- 2002-05-23 PT PT02738961T patent/PT1390042E/pt unknown
- 2002-05-23 WO PCT/NL2002/000331 patent/WO2002094279A1/en active IP Right Grant
- 2002-05-23 CA CA2448278A patent/CA2448278C/en not_active Expired - Lifetime
- 2002-05-23 US US10/478,365 patent/US7732430B2/en active Active
-
2008
- 2008-02-04 CY CY20081100136T patent/CY1108093T1/el unknown
-
2021
- 2021-07-07 NL NL301115C patent/NL301115I2/nl unknown
- 2021-07-08 LU LUC00213 patent/LUC00213I2/en unknown
- 2021-07-26 CY CY2021020C patent/CY2021020I2/el unknown
- 2021-07-27 FR FR21C1033C patent/FR21C1033I2/fr active Active
Also Published As
Publication number | Publication date |
---|---|
FR21C1033I2 (fr) | 2022-04-22 |
NL301115I1 (el) | 2021-07-14 |
CA2448278C (en) | 2010-06-08 |
NL301115I2 (nl) | 2021-10-25 |
EP1390042B1 (en) | 2007-11-28 |
FR21C1033I1 (fr) | 2021-10-15 |
LUC00213I2 (el) | 2021-10-29 |
CA2448278A1 (en) | 2002-11-28 |
CY1108093T1 (el) | 2014-02-12 |
DK1390042T3 (da) | 2008-03-31 |
CY2021020I2 (el) | 2021-12-31 |
DE60223795T2 (de) | 2008-11-27 |
US7732430B2 (en) | 2010-06-08 |
LUC00213I1 (el) | 2021-07-08 |
ES2296943T3 (es) | 2008-05-01 |
EP1390042A1 (en) | 2004-02-25 |
WO2002094279A1 (en) | 2002-11-28 |
US20040198710A1 (en) | 2004-10-07 |
PT1390042E (pt) | 2008-03-10 |
DE60223795D1 (de) | 2008-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2021020I1 (el) | Συστημα παραδοσης φαρμακων που αποτελειται απο τετραϋδροξυλιοποιημενο οιστρογονο για χρηση στην ορμονικη αντισυλληψη | |
DE60140462D1 (de) | Darreichungsform zur hormonalen kontrazeption | |
PL370889A1 (en) | Vaginal delivery of drugs | |
NO20041315L (no) | Medikamentavleveringssystem | |
ATE289500T1 (de) | Ophtalmologische medikamentenzuführvorrichtung | |
DK1473003T3 (da) | Lægemiddeladministrationsanordning | |
EP1367995A4 (en) | COMPOSITIONS AND METHODS FOR ENHANCING THE DIFFUSION OF MEDICAMENTS THROUGH AND IN EPITHELIAL TISSUES | |
HUP0700039A2 (en) | Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation | |
EE200100256A (et) | Ravimi manustamise vahend, eriti progestiinide jaöstrogeenide manustamiseks | |
AU2002241538A1 (en) | Intrasvascular drug delivery device and use therefor | |
NO20035645D0 (no) | Forsterket medikamentlevering i transdermale systemer | |
DK1409065T3 (da) | Oftalmisk medikamentafgivelsesanordning | |
HK1077523A1 (en) | Proliposomal drug delivery system | |
EP1450876A4 (en) | INTEGRATED TRANSDERMAL DRUG DELIVERY SYSTEM | |
ATE311173T1 (de) | Neues selbstemulgierendes arzneistoffverabreichungssystem | |
AU2003243439A8 (en) | Medical device for intra-lumenal delivery of pharmaceutical agents | |
EE05415B1 (et) | Ravimi manustamise vahend, eriti androgeenide manustamiseks | |
IL137559A0 (en) | Transdermal drug delivery system | |
IL139177A0 (en) | Sustained release drug delivery system | |
HUP0202741A3 (en) | Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation | |
DE10192797D2 (de) | Drug-Delivery-Systeme | |
AU2001258442A1 (en) | Drug delivery device, especially for the delivery of levonorgestrel | |
AU2001269439A1 (en) | Medicinal preparations for treating sex hormone-dependent diseases | |
AU5654701A (en) | Drug delivery mask | |
AU2002311675A1 (en) | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |